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Abstract: High sensitivity serum C-reactive protein (hs-CRP) has come into clinical use as a marker of risk for cardio-
vascular disease (CVD). In addition to a role as a marker of disease, CRP has also been implicated in the pathogenesis of 
CVD. Speciﬁ  c small-molecule inhibitors of CRP have recently been developed with the intent of mitigating cardiac damage 
during acute myocardial infarction. However, the use of CRP, both as a risk marker and a disease target are controversial for 
several reasons. Serum hs-CRP concentrations can be elevated on the basis of genetics, female gender, and non-Caucasian 
ethnicity. It is not clear, in these contexts, that elevations of hs-CRP have any pathological signiﬁ  cance. As a non-speciﬁ  c 
indicator of inﬂ  ammation, CRP is also not a speciﬁ  c indicator of a single disease state such as cardiovascular disease but 
elevated concentrations can be seen in association with other comorbidities including obesity and pulmonary disease. In sharp 
contrast to the proposed inhibition of CRP for cardiovascular disease treatment, the infusion of CRP has been shown to have 
profound therapeutic beneﬁ  ts for autoimmune disease and septic shock. The balance between the risks and beneﬁ  ts of these 
competing views of the role of CRP in disease and disease therapy is reminiscent of the ongoing controversy regarding the 
use of non-steroidal anti-inﬂ  ammatory drugs (NSAIDs) for musculoskeletal disease and their cardiovascular side effects. 
Soon, NSAIDs may not be the only agents about which Rheumatologists and Cardiologists may spar.
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Commentary
C-reactive protein (CRP) is produced by the liver as part of the ‘reorchestration’ of hepatic gene expres-
sion in response to inﬂ  ammation and infection (Black et al. 2004). An extremely sensitive acute phase 
reactant, CRP concentrations increase rapidly in serum and often exceed the reference range by 1000 
times or more (Mortensen, 2001). Its rapid synthesis after infection suggests it contributes to host 
defense (Black et al. 2004). Barring recent infections, changes in disease state, or stress, CRP baseline 
concentrations are reported to be relatively steady with minimal diurnal or seasonal variation (Meier-
Ewert et al. 2001). Moreover, unlike the cytokines, IL-6, IL-1ß, and TNF-a that elicit CRP production 
from the liver (Mortensen, 2001), this protein has a relatively long plasma half-life (19 hours) and is 
quite stable in vitro (Aziz et al. 2003). 
C-reactive protein was named for its ability to precipitate the “C” polysaccharide extracted from 
the pneumococcal cell wall (Black et al. 2004). Synthesis of the protein is now known to be stimulated 
in response to many pathogens including gram-positive (Mold et al. 1981) and gram-negative patho-
gens, fungi, and malarial parasites (Volanakis, 2001; Szalai, 2002). By binding to speciﬁ  c ligands of 
the pathogen’s cell wall, CRP activates the classical complement pathway and provides a means of 
defense against the invading pathogen. The ﬁ  nding of homologous CRP-like pentameric proteins, called 
pentraxins, in numerous vertebrates, as well as invertebrates (Magor and Magor, 2001), suggests it is 
an ancient element of an innate host immune defense strategy dependent upon the ability to opsonize 
pathogenic ligands (Tharia et al. 2002). Unlike the activation of complement by immunoglobulin, 
complement activation initiated by CRP is limited to C1-C4 by the complement-control protein, factor 
H (Giannakis et al. 2003; Du Clos, 2002; Giannakis et al. 2001). Therefore, CRP promotes phagocytosis 
of particles without generating a strong inﬂ  ammatory response (Du Clos, 2002).
C-reactive protein also exhibits a distinct anti-inﬂ  ammatory activity indicated by its protective 
effects against endotoxic shock, allergic encephalitis, inﬂ  ammatory alveolitis, nephrotoxic nephritis, and 
systemic lupus erythematosus (SLE) (Black et al. 2004; Rodriguez et al. 2005; Szalai et al. 2000). This 
activity is believed to be mediated, at least in part, by the immunosuppressive cytokine IL-10, whose 
expression is induced by CRP’s binding to Fcγ receptors on macrophages (Ogden and Elkon, 2005). In 
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addition, CRP appears to play a very important role 
in preventing autoimmunity (Du Clos and Mold, 
2004; Szalai et al. 2002; Russell et al. 2004) by 
targeting apoptotic and necrotic cells for removal. 
Of note, many of the autoantibodies commonly 
associated with SLE are directed against the major 
CRP ligands reported in the literature, namely, 
chromatin, histones, ﬁ  bronectin, small nRNPs, and 
laminin (Du Clos et al. 1991; Black et al. 2004); 
this suggests for at least this autoimmune disease, 
a failure of the normal CRP clearance mechanisms. 
However, debate continues over whether CRP 
is primarily a passive indicator of inﬂ  ammatory 
events, a “culprit” mediating disease (Rattazzi 
et al. 2003; Bisoendial et al. 2005), or nature’s 
own immunosuppressant, functioning to limit 
tissue damage, modulating acute inﬂ  ammation, 
and preventing autoimmunity.
The development of robust assays of supe-
rior sensitivity compared to those for basic CRP 
measurement, has allowed the identiﬁ  cation of 
patients with low levels of inﬂ  ammation. These 
high-sensitivity CRP (hs-CRP) assays have led to 
increasing use of this protein in the study of the 
inﬂ  ammatory nature of many chronic diseases 
such as atherosclerosis (Ridker, 2004; Armani and 
Becker, 2005). With the recognition that inﬂ  amma-
tion plays a role in CVD and precedes myocardial 
infarction, numerous reports have emerged with 
plausible explanations for an association between 
hs-CRP and CVD (Pepys and Hirschﬁ  eld, 2003) 
and for the characterization of hs-CRP as a robust 
and independent predictor of future cardiovascular 
events (Verma, 2004). The expanding interest in 
inﬂ  ammation and its relation to CVD resulted in a 
2002 workshop sponsored by the American Heart 
Association (AHA) and Centers for Disease control 
(CDC), and guidelines for the use of hs-CRP in 
the assessment of risk of such events have been 
proposed (Pearson et al. 2003). This consensus 
panel issued a statement regarding interpretive 
ranges for hs-CRP for assessment of risk for CVD 
(< 1 mg/L low risk group, 1–3 mg/L average risk 
group, and > 3 mg/L high risk group) (Pearson 
et al. 2003). Since then at least 945 clinical labo-
ratories across the country have begun performing 
hs-CRP testing as an assay to assist in the assess-
ment of CVD risk. However, the values on which 
these categories are based have been derived 
almost exclusively from Caucasian European 
and European American reference populations 
(Anand et al. 2004).
CRP is strongly associated with obesity, and 
weight loss has been shown to decrease CRP in 
nine of ten studies in which it has been evaluated 
(Dietrich and Jialal, 2005). Race and gender also 
strongly inﬂ  uence serum hs-CRP concentration 
(Khera et al. 2005). In Dallas County, character-
ized as a typical multiethnic U.S. urban popula-
tion, the median hs-CRP level is 30% higher in 
blacks than in whites, and almost twice as high 
in women as men (Khera et al. 2005). A new 
study demonstrated that cardiorespiratory ﬁ  tness 
level, hormone replacement therapy use, and 
high-density lipoprotein cholesterol accounted 
for the gender difference in hs-CRP (Huffman 
et al. 2006). It is also increasingly evident that 
genetic factors, including apoE genotype (Marz 
et al. 2004) and polymorphisms in the hs-CRP gene 
(Russell et al. 2004; Szalai et al. 2002; Suk et al. 
2005), regulate basal hs-CRP concentrations. The 
substantial variability in hs-CRP concentrations 
in people of different ethnic origins, led Anand 
et al. to conclude that uniform hs-CRP cut-points 
were not appropriate for deﬁ  ning vascular risk 
across diverse populations (Anand et al. 2004). 
Our ﬁ  ndings in an ethnically diverse population 
with comorbidities point to similar conclusions. 
In this cohort of 670 individuals (49% African 
American and 58% female), mean ln hs-CRP 
was higher in African-Americans and in women 
(p < 0.0001) and was strongly correlated with body 
mass index (r = 0.401, p < 0.0001), but not with age 
(r = 0.008, p = 0.841) (Jordan et al. 2002). In addi-
tion to ethnicity and body mass index, ln hs-CRP 
was also independently associated with chronic 
pulmonary disease. We further evaluated a subset 
of individuals in Johnston County, North Carolina, 
without self-reported cardiovascular disease and 
with a low ten-year risk for cardiovascular disease 
based upon the Framingham cardiovascular disease 
risk score (Wilson et al. 1998). Notwithstanding 
low risk by the Framingham score, the majority 
of these individuals were categorized as moderate 
or high risk for cardiovascular disease based 
upon serum hs-CRP concentration; women (even 
after excluding hormone replacement users) and 
individuals with osteoarthritis chieﬂ  y comprised 
this high-risk group based on hs-CRP (Kraus 
et al. 2006). 
Controversy also exists regarding the potential 
for CRP to act as a mediator of atherothrombotic 
disease (Pepys and Hirschfield, 2003; Pepys, 
2005). Although bacterial recombinant human CRP 
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has been shown to induce a massive acute phase 
response in humans (Bisoendial et al. 2005), these 
results, and possibly most of the proinﬂ  ammatory 
activities ascribed to CRP, may be attributable to 
contamination of CRP preparations with lipopoly-
saccharide, endotoxin, or the preservative, sodium 
azide (Pepys et al. 2005). Moreover, the description 
of CRP as a pathogenic agent underlying cardio-
vascular disease (Pearson et al. 2003; Armani and 
Becker, 2005) contrasts sharply with the generally 
protective and anti-inﬂ  ammatory action of CRP 
(Volanakis, 2001) described above. The large 
population-based Dallas Heart study has recently 
reported that hs-CRP was not independently associ-
ated with atherosclerotic burden deﬁ  ned by either 
coronary artery calciﬁ  cation on cardiac electron-
beam computed tomography scans or by abdominal 
aortic plaque on magnetic resonance images (Khera 
et al. 2006). Other recent assessments, with careful 
control for traditional risk factors for CVD, suggest 
that minimal improvement in CVD risk prediction 
is provided by hs-CRP over conventional risk 
factors (Sepulveda and Mehta, 2005). The relative 
risk ratio (RR) of hs-CRP for CVD is estimated to 
be much lower (RR=1.45) than originally reported 
(Levinson et al. 2004); used alone, hs-CRP has 
been estimated to have a very low positive predic-
tive value (≤0.86%) for predicting CVD (Levinson 
et al. 2004; Levinson, 2005). 
A small-molecule inhibitor of CRP, perhaps the 
ﬁ  rst of many to come, has recently been designed 
and synthesized (Pepys et al. 2006). This inhibitor 
abrogated the increase in infarct size and cardiac 
dysfunction produced by injection of human CRP 
in a rat model of acute myocardial infarction. Thus, 
the rationale for targeting CRP is based upon the 
ability of human CRP to increase myocardial and 
cerebral infarct size in rats subjected to coronary 
or cerebral artery ligation, respectively. However, 
this may be nothing more than an epiphenomenon 
related to the inability of the rat isoform of the 
native complement-control protein, factor H, to 
interact with human CRP. Of note, rat CRP does 
not activate rat complement, nor cause these delete-
rious effects in the rat myocardial infarction model. 
In the experiments described above, human CRP 
was required to activate rat complement. 
Ethnicity and gender exert strong inﬂ  uences 
on serum hs-CRP concentration and confound 
the prediction of CVD risk based upon hs-CRP. 
Caution is advised in the use of serum hs-CRP for 
predicting CVD or its inhibition for treating CVD 
until the consequences of CRP inhibition are better 
understood, and further conclusive evidence is 
available demonstrating a pathologic role for CRP 
in CVD, taking into account the biology of native 
interacting factors, and evaluating the pathologic 
signiﬁ  cance of CRP elevations due to ethnicity, 
gender and genetics.
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